FloraWorks Announces Scientific Breakthrough in Natural Sleep Aids: First-Ever Double-Blind, Randomized, Placebo-Controlled Clinical Trial Discovers CBN Effective for Sleep

June 28th, 2023 - Ryan Allway

Independently Conducted Trial by Radicle Science Finds Florworks’s Flagship TruCBN; Showed a Significant Improvement in Sleep When Compared to Placebo   Portland, Oregon–(Newsfile Corp. – June 28, 2023) – A landmark study led by FloraWorks Holdings Inc. (“FloraWorks” or “Company”), a leading cannabinoid therapeutics company, announced the results of the first-ever double-blind, randomized, placebo-controlled trial that analyzed the effects […]

Wana Brands CEO establishes $50M charitable foundation

November 10th, 2022 - Ryan Allway

NOVEMBER 10, 202212:32:10 PM – Nancy Whiteman, CEO and co-founder of Boulder’s Wana Brands, has launched the Wana Brands Foundation, a $50 million charitable organization.   The foundation will focus on research and education, food security, shelter, safety, mental health, sustainability, connection, and social justice.   Whiteman established the endowment from proceeds of Wana’s 2021 […]

Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement

November 7th, 2022 - Ryan Allway

Skye will continue to pursue Canadian Securities Exchange listing following closing of transaction targeting glaucoma   VANCOUVER, BC, November 7, 2022– Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (CSE: EMH; OTCQB: EMHTF) and Skye Bioscience, Inc. (“Skye”) (OTCQB: SKYE) announced today that they intend to close the previously announced Plan of Arrangement (“Arrangement”) on or […]

Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future

September 26th, 2022 - Ryan Allway

New Clinical Facility in London, Ontario Accelerates Research and Innovation   VANCOUVER, British Columbia, September 26, 2022–(BUSINESS WIRE)–Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company“) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that […]

Branded Legacy, Inc. Partners With Apple Rush Company, Inc.

September 22nd, 2022 - Ryan Allway

Company Adds New Delta-8 Tincture to Product Line   Orlando, FL , Sept. 22, 2022 (GLOBE NEWSWIRE) — Branded Legacy, Inc. (OTCQB: BLEG), a holding company focused on the commercial development of cannabinoid-infused products from CBD topicals and tinctures to edibles is pleased to announce it has partnered with Apple Rush Company, Inc., (OTC Pink: […]

22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform

May 18th, 2022 - Ryan Allway

Complete Hemp/Cannabis Solution from Receptor Science and Plant Genetics to Final Ingredients and CDMO Consistent, Reliable, High-Quality Cannabinoids and Cannabinoid Infused Products for Consumers Acquisition Immediately Accretive; Will Double 22nd Century Revenue   BUFFALO, N.Y., May 18, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human […]

MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer’s in the EU and UK

April 5th, 2022 - Ryan Allway

LONDON, April 5, 2022 /PRNewswire/ — MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.   The agreement […]

Dr AnnaRx Announces Rob Simbowe CBD Muscle and Joint Rubs

March 30th, 2022 - Ryan Allway

CAPE TOWN, SA / ACCESSWIRE / March 30, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:   Dr. AnnaRx™ is pleased to announce the launch of its new line of CBD Muscle and Joint […]

Hempsana Signs Partnership with GAMA Corp to Launch New Product Offerings and Brands

March 28th, 2022 - Ryan Allway

TORONTO, March 28, 2022–(BUSINESS WIRE)–Hempsana Holdings Ltd. (the “Company” or “Hempsana“) a leader in the production and refinement of cannabinoids and Cannabis 2.0 products, is delighted to announce that it has entered into a contract manufacturing agreement with GAMA Corp (“GAMA“) to co-manufacture and distribute new products and well recognized brands from the United States […]

Aurora Cannabis Delivers ~$10 Million Shipment of Medical Cannabis to Israel

January 4th, 2022 - Ryan Allway

• Believed to be the largest shipment of medical cannabis to Israel to-date • Aurora continues to advance strategic leadership in the global cannabinoid industry   EDMONTON, AB, Jan. 4, 2022 /CNW/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the delivery of a cannabis shipment worth […]

Jupiter Wellness Signs Definitive Agreement to Merge with Next Frontier Pharmaceuticals, a Leading Drug Developer and Manufacturer of Synthetic Cannabinoid Pharmaceuticals

December 9th, 2021 - Ryan Allway

Owner of SYNDROS®(dronabinol), the only US-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid used in adults to treat: Chemotherapy Induced Nausea and Vomiting (CINV) associated in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight loss in adult patients with Acquired Immune Deficiency Syndrome (AIDS) 83,000 […]

Nextleaf Awarded U.S. Patent and Provides Update on the Launch of Glacial Gold(TM)

September 29th, 2021 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – September 29, 2021) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf“, “OILS“, or the “Company“), a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce that the United States […]

Willow Biosciences Announces Commercial Scale Operational Update, CBGA Production Update and Corporate Update

September 21st, 2021 - Ryan Allway

VANCOUVER, BC, Sept. 21, 2021 /PRNewswire/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide the following operational and corporate updates.   Commercial Scale Operational Update In March 2021, Willow completed its first commercial scale fermentation run of […]

MariMed and Legendary Emack & Bolio’s Brand Collaborate To Create New Brand of Cannabis Infused Ice Cream

August 5th, 2021 - Ryan Allway

NORWOOD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) — MariMed, Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on health and wellness, today announced a joint collaboration with the legendary Boston ice cream brand Emack & Bolio’s®. MariMed and the ice cream magicians at Emack & Bolio’s will create a line-up […]

Bioharvest Sciences Inc.’s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

July 7th, 2021 - Ryan Allway

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks. – The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus an average of 4 cycles per year for conventional Cannabis cultivation. – The Company […]

RAMM Pharma to Acquire 100% of Leading Vertically Integrated European Cannabis Company Canapar Corp.

May 12th, 2021 - Ryan Allway

TORONTO, May 12, 2021 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM“) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, is pleased to announce that the Company has entered into a definitive acquisition agreement with Canapar Corp. (“Canapar”) and a wholly-owned subsidiary of the […]

Newly Public Gage Cannabis on a Steep Growth Trajectory

May 11th, 2021 - Robin Lefferts

  Investors looking for value in the legal cannabis industry might be looking for some key indicators to point the way to companies of interest. Organizations operating in key and lucrative markets, showing fast revenue growth that looks like it will continue, and having experienced executives to guide the company through the various pitfalls of […]

CB Therapeutics Closes on Oversubscribed Series A

May 10th, 2021 - Ryan Allway

CB Therapeutics raises Series A round with re.Mind Capital and accelerates its manufacturing and research of cannabinoids, tryptamines, and other therapeutics. Christian Angermayer joins as Advisor; the board of directors expands with additions of Dr. Srinivas Rao, CSO of Atai Life Sciences; Dr. Jeff Miller, CEO of Invivoscribe; and Jan Hardorp, Founding Partner at re.Mind […]

Halo Collective Completes Acquisition of Nature’s Best Resources

April 20th, 2021 - Ryan Allway

TORONTO, April 20, 2021 /CNW/ – Halo Collective Inc. (the “Company”) is pleased to announce it has completed its acquisition of 100% of the membership interests of Nature’s Best Resources LLC (“Nature’s Best”) in exchange for the issuance of up to 44,047,619 common shares in the capital of the Company (“Common Shares “).  35,119,048 of the Common Shares […]

What Revive’s PharmaTher Acquisition Means for Investors

March 24th, 2021 - Ryan Allway

Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) recently acquired the full rights to PharmaTher Inc.’s (CSE: PHRM) (OTC: PHRRF) intellectual property pertaining to psilocybin—the most popular psychedelic compound in clinical development worldwide. The assets include preclinical research from the National Health Research Institutes in traumatic brain injury and stroke, as well as three key provisional […]

How California is Dominating the Cannabis Brand Landscape

February 24th, 2021 - Ryan Allway

California is well known for its brand dominance—from its Hollywood studios to its Napa Valley wines. As a tastemaker across industries, the state’s cannabis brands are well-positioned to follow in these footsteps and expand across the United States if and when the federal government legalizes cannabis nationwide. At the same time, manufactured products including gummies, […]

Big Pharma Dives Into CBD: Who Could Be Next?

February 22nd, 2021 - Robin Lefferts

As many of you know, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) agreed in early February to acquire GW Pharmaceuticals plc (NASDAQ: GWPH) for a total price tag, including cash and shares, of $7.2 billion. GW Pharma is a pioneer in cannabinoid-based medicine, and its cannabidiol (CBD) formulation Epidiolex® is notably the first plant-derived cannabinoid medicine ever […]

Look for Bottom Line Performance in Cannabis Companies

February 22nd, 2021 - Robin Lefferts

  Some key features of Decibel Cannabis Company: Defining the upper echelon of premium cannabis brands with its own brand, Qwest Among the few profitable cannabis companies with growth ahead Short supplied with leading flower pricing – adding 4x flower production #1 and #3 in vapes and concentrates with 30+ product SKUs to come The […]

Next Green Wave: A Hidden Gem in the Cannabis Industry

January 28th, 2021 - Ryan Allway

  The cannabis industry is projected to hit $30 billion in sales by 2023, according to Marijuana Business Daily, with California representing about 34% of U.S. sales. While there are many publicly traded companies in the space, there are only a handful that are growing and profitable with a truly experienced team both in the […]

How to Invest in Cannabis Delivery

January 18th, 2021 - Ryan Allway

Delivery services of all kinds experienced record-breaking growth in 2020 thanks to a global pandemic that has depressed retailers, restaurants, and grocery stores. Of course, these trends are just an acceleration of an existing transition from brick-and-mortar to e-commerce—a trend that many in the cannabis industry are betting will be transformative. Let’s take a look […]

CBD Innovator, HempFusion, Makes Successful Debut on TSX

January 13th, 2021 - Ryan Allway

  HempFusion Wellness Inc. (TSX: CBD-U) shares soared over 65% following their successful debut on the Toronto Stock Exchange (TSX) on Wednesday, January 6, 2021. Cannabidiol, or CBD, has become one of the most popular health and wellness products in the world over the past couple of years. According to Research and Markets, the global […]

How to Position Your Cannabis Portfolio for a Biden Presidency

December 8th, 2020 - Ryan Allway

The House of Representatives cast a historic vote to end the nationwide prohibition on cannabis on December 4, 2020. While the MORE Act would remove cannabis from the Controlled Substances Act and decriminalize the drug across the country, the legislation will almost certainly fail to pass the Republican-controlled Senate. While decriminalization won’t happen this year, […]

HempFusion Gears Up for IPO on the TSX

December 7th, 2020 - Ryan Allway

HempFusion Wellness Inc., a leading health and wellness CBD company, recently closed the order book for its proposed initial public offering (IPO), marking another step closer to becoming a publicly-traded company on the Toronto Stock Exchange (TSX) over the coming months. Completion of this proposed initial public offering has the potential to accelerate the company’s […]

Why Focus on Cannabis & Mushroom Extracts?

November 25th, 2020 - Ryan Allway

  Cannabis extracts are poised to become a $28.5 billion market by 2027, according to Grand View Market Research, representing a 16.6% compound annual growth rate. At the same time, the functional mushroom market is forecast to reach $34.3 billion by 2024, which represents a respectable 8% compound annual growth rate. Let’s take a look […]

CBD Makes Its Way into Mainstream Retail

November 19th, 2020 - Ryan Allway

The U.S. market for CBD products is projected to reach $23.7 billion by 2023, according to Brightfield Group, representing a seven-fold increase in the market’s size. While it’s one of the fastest-growing subsets of the multi-trillion-dollar wellness industry, CBD products remain absent from most mass-market retailers. CVS became the first large-scale retailer to offer CBD […]

Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at,, or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit:

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer